

***Fiscal Year 2022 (FY22) Chronic Pain Management Research Program (CPMRP)
Reference Table of Award Mechanisms and Submission Requirements***

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Clinical Exploration Award (CEA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-22-CPMRP-CEA</p>	<p>Independent investigators at all levels</p>	<ul style="list-style-type: none"> • Supports proof-of-principle pilot studies, clinical trials, and correlative studies with the potential to resolve current clinical barriers. • Research must address one or both of the FY22 CPMRP CEA Focus Areas of chronification of pain and effectiveness or observational studies of novel or untested techniques/approaches/pathways to chronic pain management. • Explorative studies, innovative approaches, and stakeholder engagement are encouraged. • Preliminary data are not required. • Statistically underpowered studies of efficacy are not pilot studies and will not be supported under the FY22 CPMRP CEA mechanism. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$250,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 2 years. 	<p>Pre-Application (Preproposal): July 12, 2022 5:00 p.m. Eastern time</p> <p>Application: October 13, 2022 11:59 p.m. Eastern time</p>
<p>Investigator-Initiated Research Award (IIRA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-22-CPMRP-IIRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports innovative research that will make an original and important contribution to the field of research, patient care, and/or quality of life. • Research must address one of more of the FY22 CPMRP IIRA Focus Areas of chronification of pain, effectiveness or observational studies of novel or untested techniques/approaches/pathways to chronic pain management, or development of non-opioid therapies and methods of treatment of chronic pain. • Partnering Principal Investigator (PI) Option is available. • Multidisciplinary collaborations, innovative approaches, and stakeholder engagement are encouraged. • Clinical trials will not be funded. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$900,000 for direct costs. • Indirect costs may be proposed in accordance with the institution’s negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): July 12, 2022 5:00 p.m. Eastern time</p> <p>Application: October 13, 2022 11:59 p.m. Eastern time</p>

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
<p>Translational Research Award (TRA)</p> <p>Go to:</p> <ul style="list-style-type: none"> • Program Announcement • General Application Instructions <p>Grants.gov Funding Opportunity Number:</p> <p>W81XWH-22-CPMRP-TRA</p>	<p>Investigators at or above the level of Assistant Professor (or equivalent)</p>	<ul style="list-style-type: none"> • Supports translational research that will accelerate the movement of efficacious, evidence-based ideas into clinical applications. • Research must address one or more of the FY22 CPMRP TRA Focus Areas of implementation science, comparative effectiveness, or observational studies related to chronic pain. • Incorporation of stakeholder engagement is required. • Biopsychosocial models of assessment are encouraged. • Partnering PI Option is available. • Studies seeking to evaluate new therapies or approaches, either pharmacological or non-pharmacological, that have not been previously evaluated in a clinical setting will not be funded. • <i>Pre-application submission is required; application submission is by invitation only.</i> 	<ul style="list-style-type: none"> • The maximum allowable funding for the entire period of performance is \$1,400,000 for direct costs. • Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. • The maximum period of performance is 4 years. 	<p>Pre-Application (Preproposal): July 12, 2022 5:00 p.m. Eastern time</p> <p>Application: October 13, 2022 11:59 p.m. Eastern time</p>